This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Macrophage Therapy for Liver Disease
Tech medical breakthrough

Macrophage Therapy for Liver Disease

Analysis based on 8 articles · First reported May 25, 2026 · Last updated May 25, 2026

Sentiment
80
Attention
6
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

This medical breakthrough by the University of Edinburgh and Paragon Therapeutics offers a potential alternative to liver transplants, which could significantly impact the healthcare and biotechnology sectors. The positive clinical trial results for the macrophage therapy could lead to increased investment and market valuation for companies involved in regenerative medicine and cell therapies, particularly for Paragon Therapeutics as they advance their RTX001 therapy.

Biotechnology Healthcare Pharmaceuticals
Event Summary

Scientists at the University of Edinburgh, led by Professor Stuart Forbes, have developed a pioneering cell therapy for advanced liver disease. This macrophage therapy, tested in the MATCH clinical trial, significantly lowered the risk of death or the need for a liver transplant after four years compared to standard care. The treatment involves taking immune cells from patients' blood, converting them into macrophages, and re-injecting them to break down scar tissue, reduce inflammation, and encourage healthy liver cell growth. Professor Stuart Forbes co-founded Paragon Therapeutics to commercialize this science, and the company is now testing a new version, RTX001, in the EMERALD clinical trial. This breakthrough offers 'real hope' for patients with end-stage liver disease, potentially reducing the reliance on limited liver donor organs. The study was funded by the United Kingdom — Medical Research Council and United Kingdom — Chief Scientist Office and published in Cell Stem Cell.

Entities Involved
priv
Paragon Therapeutics
Paragon Therapeutics is a spinout company co-founded by Professor Stuart Forbes to commercialize the macrophage therapy. The company is currently testing a new version of the therapy, RTX001, in the EMERALD clinical trial, indicating significant progress and potential for future market impact.
Importance 95.0 Sentiment 90.0
per
Stuart Forbes
Professor Stuart Forbes, from the University of Edinburgh, led the research team that developed the macrophage therapy and co-founded Paragon Therapeutics. His work is central to this medical breakthrough.
Importance 90.0 Sentiment 85.0
govactor
United Kingdom — Scottish National Blood Transfusion Service
The United Kingdom — Scottish National Blood Transfusion Service collaborated with Professor Stuart Forbes in developing the macrophage therapy. Their involvement highlights the collaborative nature of the research.
Importance 40.0 Sentiment 60.0
ngo
British Liver Trust
The British Liver Trust welcomed the findings and supported the study, emphasizing the 'real hope' this treatment offers to patients with cirrhosis. They played a role in patient involvement and advocacy.
Importance 30.0 Sentiment 60.0
govactor
United Kingdom — Chief Scientist Office
The United Kingdom — Chief Scientist Office also funded the study, contributing to the advancement of this cell therapy research.
Importance 20.0 Sentiment 60.0
govactor
United Kingdom — Medical Research Council
The United Kingdom — Medical Research Council funded the study, demonstrating government support for medical research in the United Kingdom.
Importance 20.0 Sentiment 60.0
cnt
United Kingdom
The United Kingdom is the location where the research was conducted and where the British Liver Trust operates, indicating the national context of this medical development.
Importance 10.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.